Achieve Life Sciences (ACHV) Return on Capital Employed (2011 - 2018)
Achieve Life Sciences (ACHV) recorded quarterly Return on Capital Employed of 85.3% in Q4 2018, down 1.71% on a QoQ basis from 83.87% in Q3 2018, and up 5903.0% year-over-year from 1.42% in Q4 2017.
Achieve Life Sciences (ACHV) Return on Capital Employed (2011 - 2018) Analysis & Trends
Achieve Life Sciences has disclosed Return on Capital Employed across 6 years of filings, most recently posting 85.3% for Q4 2018.
- Quarterly Return on Capital Employed rose 5903.0% year-over-year to 85.3% in Q4 2018, while the trailing twelve-month figure through Dec 2018 was 85.3% (up 5903.0% YoY) and the FY2019 annual result came in at 95.25%, up 1784.0% from the prior year.
- Return on Capital Employed slipped to 85.3% in Q4 2018, from 83.87% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 10.34% in Q2 2017 and troughed at 246.5% in Q4 2016.
- A 4-year average of 115.41% and a median of 90.41% in 2017 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2017 — Return on Capital Employed surged 10218 bps — and 2018, when it slumped 20873 bps.
- Tracing ACHV's Return on Capital Employed over 4 years: stood at 58.96% in 2015, then plunged by 318 bps to 246.5% in 2016, then soared by 41 bps to 144.32% in 2017, then jumped by 41 bps to 85.3% in 2018.
- Business Quant data shows ACHV's Return on Capital Employed at 85.3% in Q4 2018, 83.87% in Q3 2018, and 170.79% in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -85.30% |
| Sep 30, 2018 | -83.87% |
| Jun 30, 2018 | -170.79% |
| Mar 31, 2018 | -237.82% |
| Dec 31, 2017 | -144.32% |
| Sep 30, 2017 | -90.41% |
| Jun 30, 2017 | -10.34% |
| Mar 31, 2017 | -29.09% |
| Dec 31, 2016 | -246.50% |
| Sep 30, 2016 | -112.10% |
| Dec 31, 2015 | -58.96% |
| Dec 31, 2012 | -37.63% |
| Sep 30, 2012 | -13.65% |
| Jun 30, 2012 | -18.09% |
| Mar 31, 2012 | -26.69% |
| Dec 31, 2011 | -39.23% |
| Sep 30, 2011 | 1.84% |